Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Bevacizumab (BEV), a humanized monoclonal antibody, become a currently important chemotherapeutic option for the patients with recurrent glioma. The aim of this retrospective study is to investigate whether 18F-Fluoromisonidazole (FMISO) PET have the potential to detect BEV-resistant gliomas in the...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5148016?pdf=render |
| _version_ | 1811208838992363520 |
|---|---|
| author | Shigeru Yamaguchi Kenji Hirata Takuya Toyonaga Kentaro Kobayashi Yukitomo Ishi Hiroaki Motegi Hiroyuki Kobayashi Tohru Shiga Nagara Tamaki Shunsuke Terasaka Kiyohiro Houkin |
| author_facet | Shigeru Yamaguchi Kenji Hirata Takuya Toyonaga Kentaro Kobayashi Yukitomo Ishi Hiroaki Motegi Hiroyuki Kobayashi Tohru Shiga Nagara Tamaki Shunsuke Terasaka Kiyohiro Houkin |
| author_sort | Shigeru Yamaguchi |
| collection | DOAJ |
| description | Bevacizumab (BEV), a humanized monoclonal antibody, become a currently important chemotherapeutic option for the patients with recurrent glioma. The aim of this retrospective study is to investigate whether 18F-Fluoromisonidazole (FMISO) PET have the potential to detect BEV-resistant gliomas in the early-stage.We reviewed the FMISO PET and MRI appearances before and 3 to 4 courses after BEV treatment on 18 recurrent glioma patients. FMISO accumulation was assessed by visual inspection and semi-quantitative values which were tumor-to-normal (T/N) ratio and hypoxic volume. MRI responses were evaluated based on RANO (Response Assessment in Neuro-Oncology) criteria. The prognostic analysis was performed in relation to the response assessment by FMISO PET and MRI using overall survival (OS) after BEV application.After BEV application, MRI revealed partial response in 14 of 18 patients (78%), of which 9 patients also demonstrated decreased FMISO accumulation. These 9 patients (50%) were classified as "MRI-FMISO double responder". As for the other 5 patients (28%), FMISO accumulation volumes increased or remained stable after BEV treatment although partial responses were achieved on MRI. Therefore, these cases were classified as "MRI-only responder". The remaining 4 patients (22%) did not show treatment response on FMISO PET or MRI ("non-responder"). MRI-FMISO double responders showed significantly longer OS than that in other groups (median 12.4 vs 5.7 months; P < 0.001), whereas there were no overall survival difference between MRI-only responders and non-responders (median OS, 5.7 and 4.8 months; P = 0.58). Among the pre-treatment clinical factors, high FMISO T/N ratio was a significant prognostic factor of overall survival in these patients under the assessment of Cox proportional hazard model.Recurrent gliomas with decreasing FMISO accumulation after short-term BEV application could derive a survival benefit from BEV treatment. Change in FMISO PET appearance can identify BEV-resistant gliomas in early-stage regardless of MRI findings in a comprehensible way. |
| first_indexed | 2024-04-12T04:28:28Z |
| format | Article |
| id | doaj.art-fde07bda17df49e9be467ce42f608bf3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T04:28:28Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-fde07bda17df49e9be467ce42f608bf32022-12-22T03:48:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016791710.1371/journal.pone.0167917Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.Shigeru YamaguchiKenji HirataTakuya ToyonagaKentaro KobayashiYukitomo IshiHiroaki MotegiHiroyuki KobayashiTohru ShigaNagara TamakiShunsuke TerasakaKiyohiro HoukinBevacizumab (BEV), a humanized monoclonal antibody, become a currently important chemotherapeutic option for the patients with recurrent glioma. The aim of this retrospective study is to investigate whether 18F-Fluoromisonidazole (FMISO) PET have the potential to detect BEV-resistant gliomas in the early-stage.We reviewed the FMISO PET and MRI appearances before and 3 to 4 courses after BEV treatment on 18 recurrent glioma patients. FMISO accumulation was assessed by visual inspection and semi-quantitative values which were tumor-to-normal (T/N) ratio and hypoxic volume. MRI responses were evaluated based on RANO (Response Assessment in Neuro-Oncology) criteria. The prognostic analysis was performed in relation to the response assessment by FMISO PET and MRI using overall survival (OS) after BEV application.After BEV application, MRI revealed partial response in 14 of 18 patients (78%), of which 9 patients also demonstrated decreased FMISO accumulation. These 9 patients (50%) were classified as "MRI-FMISO double responder". As for the other 5 patients (28%), FMISO accumulation volumes increased or remained stable after BEV treatment although partial responses were achieved on MRI. Therefore, these cases were classified as "MRI-only responder". The remaining 4 patients (22%) did not show treatment response on FMISO PET or MRI ("non-responder"). MRI-FMISO double responders showed significantly longer OS than that in other groups (median 12.4 vs 5.7 months; P < 0.001), whereas there were no overall survival difference between MRI-only responders and non-responders (median OS, 5.7 and 4.8 months; P = 0.58). Among the pre-treatment clinical factors, high FMISO T/N ratio was a significant prognostic factor of overall survival in these patients under the assessment of Cox proportional hazard model.Recurrent gliomas with decreasing FMISO accumulation after short-term BEV application could derive a survival benefit from BEV treatment. Change in FMISO PET appearance can identify BEV-resistant gliomas in early-stage regardless of MRI findings in a comprehensible way.http://europepmc.org/articles/PMC5148016?pdf=render |
| spellingShingle | Shigeru Yamaguchi Kenji Hirata Takuya Toyonaga Kentaro Kobayashi Yukitomo Ishi Hiroaki Motegi Hiroyuki Kobayashi Tohru Shiga Nagara Tamaki Shunsuke Terasaka Kiyohiro Houkin Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. PLoS ONE |
| title | Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. |
| title_full | Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. |
| title_fullStr | Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. |
| title_full_unstemmed | Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. |
| title_short | Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. |
| title_sort | change in 18f fluoromisonidazole pet is an early predictor of the prognosis in the patients with recurrent high grade glioma receiving bevacizumab treatment |
| url | http://europepmc.org/articles/PMC5148016?pdf=render |
| work_keys_str_mv | AT shigeruyamaguchi changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT kenjihirata changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT takuyatoyonaga changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT kentarokobayashi changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT yukitomoishi changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT hiroakimotegi changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT hiroyukikobayashi changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT tohrushiga changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT nagaratamaki changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT shunsuketerasaka changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment AT kiyohirohoukin changein18ffluoromisonidazolepetisanearlypredictoroftheprognosisinthepatientswithrecurrenthighgradegliomareceivingbevacizumabtreatment |